Palex Medical, a national leader in precision oncology, and Inbiomotion, a spin-off of IRB Barcelonaand ICREA, have signed an agreement to start marketing MAF-TEST®, initially in Spain and Portugal. The MAF-TEST® predicts the prognosis of breast cancer patients and helps oncologists to identify those patients who may be able to prevent recurrence and benefit from adjuvant treatment with bisphosphonates, which are commonly used to treat osteoporosis. The test also identifies those patients whose prognosis would worsen if treated with bisphosphonates.
Thanks to this agreement, Spain will become the first country in the world to have this test, which could increase the survival of 8 out of 10 of the 30,000 early-stage breast cancer patients diagnosed each year in Spain.
Xavier Carbonell, CEO of Palex Medical, assures that “Palex Medical has always prided itself on being able to bring the latest technology to healthcare professionals and their patients. This agreement is a double source of pride for us because not only will we beable to help thousands of women with cancer, but we will also do it through a pioneering collaboration with a national company like Inbiomotion“.
Joël Jean-Mairet, Executive Chairperson of Inbiomotion since 2012 and Executive Chairperson of Ysios Capital, also a CataloniaBio & HealthTech member, comments, “Ysios has played a very active role as a major investor in the company since its inception, with the clear objective of developing a test that will have a major impact on precision medicine in breast cancer patients. From the beginning, we have captured the interest of world opinion leaders and patients, who have helped us and pushed us to develop the MAF-TEST® so that its usefulness inbreast cancer patients becomes a reality. We are now starting to market it in Spain and Portugal through Palex, markets in which Palex has the exclusive rights and a strong presence. We are working so that MAF-TEST® will soon be available to medical practice in other countries as well“.
Approximately 1 in 8 women will develop breast cancer in their lifetime and, of these, 15-20% will eventually develop metastases. Therefore, being able to identify those patients with a higher risk of recurrence and being able to personalize their treatment is vital for their survival and quality of life.
Related news:
Comments